Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge | Zendy

Dorothy I. Jones | Zendy; Charles E. McGee | Zendy; Christopher Sample | Zendy; Gregory D. Sempowski | Zendy; David J. Pickup | Zendy; Herman F. Staats | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

Author(s) -

Dorothy I. Jones,

Charles E. McGee,

Christopher Sample,

Gregory D. Sempowski,

David J. Pickup,

Herman F. Staats

Publication year - 2016

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00216-16

Subject(s) - vaccinia , vaccination , smallpox vaccine , smallpox , virology , virus , nasal administration , modified vaccinia ankara , medicine , smallpox virus , immunology , biology , biochemistry , gene , recombinant dna

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research